(You can read the full research report on Adobe here >>>) Amgen’s shares have gained +28.4% over the past three months against the Zacks Biomedical and Genetics industry’s rise of +35.3%.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.